Related Experiment Video
Updated: Aug 15, 2026

Toxoplasma gondii Cyst Wall Formation in Activated Bone Marrow-derived Macrophages and Bradyzoite Conditions
Published on: August 12, 2010
The Mallory body as an aggresome: in vitro studies
1Department of Pathology, Harbor-UCLA Medical Center, Torrance, California 90509, USA.
Abstract:
Prior in vivo studies supported the concept that Mallory bodies (MBs) are aggresomes of cytokeratins 8 and 18. However, to test this hypothesis an in vitro model is needed to study the dynamics of MB formation. Such a study is difficult because MBs have never been induced in tissue culture. Therefore, MBs were first induced in vivo in drug-primed mice and then primary cultures of hepatocytes from these mice were studied. Two approaches were utilized: 1. Primary cultures were transfected with plasmids containing the sequence for cytokeratin 18 (CK 18) tagged with green fluorescent protein (GFP). 2. Immunofluorescent staining was used to localize the ubiquitin-proteasome pathway components involved in MB-aggresome complex formation in primary hepatocyte cultures. The cells were double stained with a ubiquitin antibody and one of the following antibodies: CK 8, CK 18, tubulin, mutant ubiquitin (UBB+1), transglutaminase, phosphothreonine, and the 20S and 26S proteasome subunits P25 and Tbp7, respectively. In the first approach, fluorescence was observed in keratin filaments and MBs 48 h after the cells were transfected with the CK 18 GFP plasmid. Nascent cytokeratin 18 was preferentially concentrated in MBs. Less fluorescence was observed in the normal keratin filaments. This indicated that MBs continued to form in vitro. The immunofluorescent staining of the hepatocytes showed that CK 8 and 18, ubiquitin, mutant ubiquitin (UBB+1), P25, Tbp7, phosphothreonine, tubulin, and transglutaminase were all located at the border or the interior of the MB. These results support the concept that MBs are aggresomes of CK 8 and CK18 and are a result of inhibition of the ubiquitin-proteasome pathway of protein degradation possibly caused by UBB+1.
Insights
Mallory bodies (MBs) are aggresomes of cytokeratins 8 and 18. This study developed an in vitro model to show MBs form in cultured hepatocytes, involving the ubiquitin-proteasome pathway.
Area of Science:
- Cell Biology
- Hepatology
- Protein Degradation
Background:
- Mallory bodies (MBs) are protein aggregates found in liver cells.
- Previous studies suggested MBs are aggresomes of cytokeratins 8 and 18 (CK 8/18).
- An in vitro model was lacking to study MB formation dynamics.
Purpose of the Study:
- To establish an in vitro model for studying Mallory body formation.
- To investigate the role of cytokeratins and the ubiquitin-proteasome pathway in MB formation.
- To confirm MBs as aggresomes of CK 8/18 in a controlled experimental setting.
Main Methods:
- Induced MBs in vivo in drug-primed mice.
- Established primary hepatocyte cultures from these mice.
- Utilized CK 18 tagged with green fluorescent protein (GFP) for transfection.
- Performed immunofluorescent staining for CK 8, CK 18, ubiquitin, and proteasome components.
Main Results:
- Transfected hepatocytes showed nascent CK 18 GFP concentrated in MBs, confirming in vitro formation.
- Immunofluorescence localized CK 8, CK 18, ubiquitin, and proteasome components (P25, Tbp7) within or at the border of MBs.
- Mutant ubiquitin (UBB+1) and other markers like phosphothreonine and tubulin were also found in MBs.
Conclusions:
- This study successfully established an in vitro model for Mallory body formation.
- Results support the hypothesis that MBs are aggresomes of CK 8/18.
- MB formation appears linked to the inhibition of the ubiquitin-proteasome pathway, potentially due to factors like UBB+1.
More Related Videos
09:16Exogenous Administration of Microsomes-associated Alpha-synuclein Aggregates to Primary Neurons As a Powerful Cell Model of Fibrils Formation
Published on: June 26, 2018
07:30Basement Membrane Matrix Encapsulated Cell Aggregation for Investigating Murine Spleen Tissue Formation
Published on: June 28, 2024